Abstract
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18–59-year-olds and 14% in 60–85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.
Cite
CITATION STYLE
Huiberts, A. J., de Gier, B., Hoeve, C. E., de Melker, H. E., Hahné, S. J. M., den Hartog, G., … Knol, M. J. (2023). Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022. Eurosurveillance, 28(7). https://doi.org/10.2807/1560-7917.ES.2023.28.7.2300087
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
